Cut rating on Dabur to ‘hold’ from ‘buy’ following outperformance relative to peers

By: |
November 5, 2020 12:15 AM

Notable revenue growth. After declining for two consecutive quarters, Dabur’s Q2 revenue grew 14% YoY, a material beat of our and consensus estimates.

The healthcare segment continued to outperform, with revenue up 49% YoY as consumers remained focused on wellness and immunity.The healthcare segment continued to outperform, with revenue up 49% YoY as consumers remained focused on wellness and immunity.

Domestic volume growth of c.17% was the key highlight of Dabur’s Q2FY21. While healthcare continued its strong run, HPC also picked up. We believe the CEO’s strategy is working well, as Dabur is becoming agile and the team is taking risks, as is evident in a slew of launches. The CEO intends to raise ad-spend in the medium term, which also highlights the growth mindset. We cut our rating on Dabur to ‘hold’ from ‘buy’ following its outperformance relative to peers.

Notable revenue growth. After declining for two consecutive quarters, Dabur’s Q2 revenue grew 14% YoY, a material beat of our and consensus estimates. Delving deeper, the India business grew by a notable 20% (volumes up c.17%), the highest in nine quarters. International business also recovered, growing 5.5% YoY (c/c: 3.5%).

Segmental performance. The healthcare segment continued to outperform, with revenue up 49% YoY as consumers remained focused on wellness and immunity. HPC, too, made a strong comeback, growing 9% YoY, with oral care an emerging bright spot. Foods remained weak, down 4% YoY.

Healthcare accelerates. Healthcare gathered further momentum, with growth accelerating to 49% from 29% in Q1. This was marked by a doubling of Chyawanprash revenues, double-digit growth in honey, and 56% growth in OTC. Growth was driven by higher household penetration, as Covid concerns drove immunity-boosting supplements.

HPC recovers. HPC recovered after two quarters of double-digit decline, led by strong growth in oral care (+24% YoY) and skincare & salon (+38% YoY). Sanitiser sales, however, declined to Rs120 million vs Rs800 million in Q1. Hair oil fell 2.5%, partly because of pressure in the CSD channel (flat ex-CSD) with consumers down trading from premium brands. Home care declined 10%, with subdued performance in Odonil and Odomos.

Foods weak, but better QoQ. The foods business fell 4% YoY, better than 35% decline in Q1. Demand in the institutional channel remain weak (ex-HORECA, revenue up 8.5%), even as in-home consumption continues to do better.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Usual Thanksgiving trade spoiled by pandemic; travel stocks refuse to fly any higher
2Robinhood of Indian stock broking: Traditional brokers open up low-cost trading for retail investors
3Buy these two stocks for gains in coming weeks to beat any short-term trend reversal in Nifty